Cell Signaling & Oncology
The signaling pathways controlling cell growth and differentiation are almost invariably altered in cancer. During the course of tumor progression, cancer cells acquire a number of characteristic alterations. These include the capacities to proliferate independently of exogenous growth-promoting or growth-inhibitory signals, to invade surrounding tissues and metastasize to distant sites, to elicit an angiogenic response, and to evade mechanisms that limit cell proliferation, such as apoptosis and replicative senescence. These properties reflect alterations in the cellular signaling pathways that in normal cells control cell proliferation, motility, and survival. These interconnected pathways are being deciphered, but understanding the alterations that lead to cancer and correcting them is a substantial challenge. Among the key pathways are those controlling cell proliferation, which coordinate a response to the cellular environment, with the mTOR kinase as a critical node. Tumour development is influenced by infections and inflammation, and the complex role of the nuclear factor-B transcription factors is being unravelled. Expansion of tumour cells depends on nutrient supply and vascularization, which is orchestrated by the transcription factor known as HIF. And the metastatic spread of primary tumours to other organs is facilitated by many signaling pathways[1],[2].
Cell Signaling and Oncology products Library
For your convenience, you can order a library of all of our Cell Signaling and Oncology research related products. Make your personal library by cherry picking products of your interest from our comprehensive list (>800 products), or order all together not to miss any. The libraries will be shipped as 10 mM solutions (in DMSO, 250 µL of each selected Axon Ligand™) on a 96-well microtiter plate with a clear map of its contents.
Simply download our comprehensive list of epigenetics products below (Microsoft Excel (.xls)), check the products to be included, and return your list to order the library of your preference.
 Axon 5051 - Cell signaling and Oncology Library.xls |
|
[1] A. Eccleston, R. Dhand. Signalling in cancer. Nature 441, 423, editorial note
[2] G.S. Martin. Cell signaling and cancer. Cancer Cell. 2003 Sep;4(3):167-74.
| Axon ID | Name | Description | From price | |
|---|---|---|---|---|
| 2611 | APS-2-79 | Inhibitor of KSR and oncogenic Ras signaling | €90.00 | |
| 2191 | AR 244555 | Inverse agonist of Mas G-protein signaling | €125.00 | |
| 2394 | AR-42 | HDAC inhibitor | €125.00 | |
| 2136 | AR03 | Inhibitor of apurinic/apyrimidinic endonuclease 1 (APE1) | €105.00 | |
| 2679 | AR7 | RARα antagonist that stimulates chaperone-mediated autophagy | €90.00 | |
| 3433 | ARB-272572 | Potent, cellular active PD-L1 inhibitor | €150.00 | |
| 2307 | ARM1 hydrobromide | Novel type of LTA4H inhibitor that selectively blocks the conversion of LTA4 into LTB4 | €92.00 | |
| 3041 | ARN 3236 | Potent, selective, ATP-competitive, and orally available inhibitor of SIK2 | €95.00 | |
| 1979 | ARN 509 | Antagonist of androgen receptor (AR) | €95.00 | |
| 3220 | ARN24139 | Orally active topoisomerase II poison | €130.00 | |
| 1838 | ARQ 197 | c-MET tyrosine kinase Inhibitor | €90.00 | |
| 3084 | ARS-1620 | Potent, selective, and orally bioavailable covalent KRAS-G12C inhibitor | €145.00 | |
| 1992 | AS 1517499 | Potent and selective STAT6 inhibitor | €130.00 | |
| 2839 | AS 1842856 | Inhibitor of the Forkhead box protein O1 (FOXO1) | €95.00 | |
| 2187 | AS 1892802 | Potent, selective, ATP-competitive ROCK inhibitor | €95.00 | |
| 1424 | AS 252424 | PI3K inhibitor (p110-γ specific) | €85.00 | |
| 1436 | AS 252424 bispotassium salt | PI3K inhibitor (p110-γ specific) | €95.00 | |
| 2578 | ASB14780 | Potent, orally available inhibitor of cPLA2α; antiinflammatory drug | €120.00 | |
| 2757 | Asciminib | Potent and selective allosteric BCR-ABL1 inhibitor | Recently added | €120.00 |
| 2179 | ASK1 Inhibitor 10 | Potent, selective, and orally bioavailable ASK1 inhibitor | €130.00 | |
| 1675 | Asoprisnil | Progesterone receptor (PR) modulator | €130.00 | |
| 2005 | ASP 3026 | Inhibitor of the oncogenic fusion kinase EML4-ALK | €80.00 | |
| 2787 | ASP 9521 | Inhibitor of 17 β–hydroxysteroid dehydrogenase type 5 | €75.00 | |
| 1986 | AST 1306 tosylate | ErbB2 and EGFR inhibitor | €90.00 | |
| 2166 | AT 13148 dihydrochloride | ATP-competitive inhibitor of multi-AGC kinases | €70.00 | |
| 1539 | AT 7519 mesylate | CDK inhibitor | €80.00 | |
| 2219 | AT 9283 | Multitargeted kinase inhibitor (Aurora A/B, JAK2/3, and BCR-Abl) | €85.00 | |
| 2043 | Atorvastatin calcium | Inhibitor of HMG-CoA reductase | €60.00 | |
| 2960 | ATR-101 | Potent, selective, and orally active ACAT1 inhibitor | €145.00 | |
| 1597 | Aurora A inhibitor I | Aurora A inhibitor | €125.00 | |